{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["tislelizumab","platinum-based chemotherapy","stereotactic body radiotherapy"]],"indication":"resectable stage II–III EGFR wild-type non-small-cell lung cancer","name":"SACTION01","nct_id":"NCT05319574","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=saction01-nct05319574. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SACTION01","arms":[{"description":"Stereotactic body radiation therapy (8Gy\\*3d) followed by Tislelizumab (200mg) with platinum-based doublet chemotherapy administered pre-operatively every 3 weeks for 2 cycles before surgical resection","label":"Neoadjuvant SBRT plus immunochemotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-05-31","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":46,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"SBRT","otherNames":["stereotactic body radiation therapy"],"type":"RADIATION"},{"name":"Tislelizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"Sun Yat-sen University","official_title":"Preoperative Stereotactic Body Radiotherapy and Platinum-based Doublet Chemotherapy Plus Tislelizumab (Immunotherapy) for Operable Stage II to III EGFR Wild-type Non-small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2023-06-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"Major Pathological Response (MPR)","timeFrame":"From date of enrollment until one month after resection"}],"references":[{"citation":"Zhao ZR, Liu SL, Zhou T, Chen G, Long H, Su XD, Zhang X, Fu JH, Lin P, Zhang LJ, Rong TH, Wu JD, Li ZC, Su HL, Chen JY, Yang YP, Lin YB, Xi M, Yang H. Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial. Lancet Respir Med. 2024 Dec;12(12):988-996. doi: 10.1016/S2213-2600(24)00215-7. Epub 2024 Sep 18.","pmid":"39305910","type":"DERIVED"}],"start_date":{"date":"2022-04-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05319574"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/saction01-nct05319574"}